AVL9: A Potential Drug Target and Biomarker for Cell Migration

Target Name: AVL9

NCBI ID: G23080

AVL9

AVL9: A Potential Drug Target and Biomarker for Cell Migration

Cell migration is a critical process in various biological processes, including tissue growth, repair, and regeneration. During cell migration, cells are guided by various factors, including the presence of extracellular matrix (ECM) components, chemotactic factors, and mechanical forces. One of theECM components that play a significant role in cell migration is the intercellular adhesion molecule (ICAM) complex. The AVL9 protein is a member of the ICAM family and has been shown to be involved in cell migration and ECM formation.

In this article, we will discuss the AVL9 protein and its potential as a drug target and biomarker for cell migration. We will review the current literature on AVL9 and its role in cell migration, as well as its potential as a drug target.

The AVL9 Protein

The AVL9 protein is a 21-kDa protein that belongs to the ICAM family. It is expressed in various tissues and cells, including epithelial, mesenchymal, and neural cells. AVL9 has been shown to play a role in cell adhesion, migration, and ECM formation.

One of the key functions of AVL9 is its ability to interact with ECM components, such as cadherins and integrins. These interactions allow AVL9 to regulate the movement of cells along the ECM during cell migration. Additionally, AVL9 has been shown to play a role in the formation of ECM, where it can interact with other ECM components to regulate the mechanical forces that drive cell migration.

In addition to its role in cell adhesion and migration, AVL9 has also been shown to play a role in the regulation of cell survival. Studies have shown that AVL9 can interact with various cellular signaling pathways, including the TGF-β pathway, which is involved in cell growth, survival, and angiogenesis.

Potential Drug Target

The AVL9 protein has great potential as a drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. One of the key reasons for its potential as a drug target is its involvement in multiple cellular signaling pathways, which makes it difficult to target specific signaling pathways.

In addition, AVL9 has been shown to interact with a variety of small molecules, including inhibitors of the TGF-β pathway. This suggests that AVL9 may be a good candidate for drugs that are designed to inhibit TGF-β signaling, which could be useful for the treatment of various diseases.

Biomarker

AVL9 has also been shown to be a potential biomarker for cell migration. The presence of AVL9 in cell migration assays has been shown to be correlated with the number of migrating cells. This suggests that AVL9 may be a useful biomarker for the assessment of cell migration.

Conclusion

In conclusion, AVL9 is a protein that has been shown to play a role in cell migration and ECM formation. Its potential as a drug target and biomarker make it an attractive candidate for the treatment of various diseases. Further research is needed to fully understand the role of AVL9 in cell migration and its potential as a drug target.

Protein Name: AVL9 Cell Migration Associated

Functions: Functions in cell migration

The "AVL9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AVL9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets